<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294160</url>
  </required_header>
  <id_info>
    <org_study_id>CADPT01C12101</org_study_id>
    <nct_id>NCT04294160</nct_id>
  </id_info>
  <brief_title>A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer</brief_title>
  <official_title>A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase Ib, open-label platform study of select drug combinations chosen in order to&#xD;
      characterize safety and tolerability of each treatment arm tested and to identify recommended&#xD;
      doses and regimens for future studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase Ib, multi-center, open-label study with multiple treatment arms in adult&#xD;
      patients with advanced or metastatic BRAF V600 (E, D, or K) in order to characterize safety&#xD;
      and tolerability of each treatment arm tested and to identify recommended doses and regimens&#xD;
      for future studies. The open platform design of this study is adaptive to allow removal of&#xD;
      combination treatment arm(s) based on emerging data and facilitate introduction of new&#xD;
      candidate combinations. The study is comprised of a dose escalation part and may be followed&#xD;
      by a dose expansion part for any combination treatment arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Anticipated">August 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) in the first cycle</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses (RD) and regimens for future studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, and ECGs</measure>
    <time_frame>34 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose interruptions</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose reductions</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast derived from Serum/plasma concentration of individual investigational drugs within combination treatments</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PK of each investigational drug within each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the PD marker DUSP6 in tumor tissue (dose escalation only)</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate PD effect in their respective combinations in tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau derived from Serum/plasma concentration of individual investigational drugs within combination treatments</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PK of each investigational drug within each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PK of each investigational drug within each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PK of each investigational drug within each treatment arm</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">395</enrollment>
  <condition>BRAF V600 Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 backbone arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 + trametinib triplet arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 + LXH254 triplet arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 + TNO155 triplet arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 + spartalizumab triplet arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + trametinib + TNO155 triplet arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Capsule for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + LXH254 triplet arm 2</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + TNO155 triplet arm 3</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + spartalizumab triplet arm 4</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + trametinib triplet arm 1</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 backbone arm 1</arm_group_label>
    <arm_group_label>Dabrafenib + trametinib + TNO155 triplet arm 5</arm_group_label>
    <other_name>DRB436, Tafinlar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTT462</intervention_name>
    <description>Capsule for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + LXH254 triplet arm 2</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + TNO155 triplet arm 3</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + spartalizumab triplet arm 4</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + trametinib triplet arm 1</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 backbone arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Tablet for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + trametinib triplet arm 1</arm_group_label>
    <arm_group_label>Dabrafenib + trametinib + TNO155 triplet arm 5</arm_group_label>
    <other_name>TMT212, Mekinist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LXH254</intervention_name>
    <description>Tablet for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + LXH254 triplet arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNO155</intervention_name>
    <description>Capsule for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + TNO155 triplet arm 3</arm_group_label>
    <arm_group_label>Dabrafenib + trametinib + TNO155 triplet arm 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Spartalizumab</intervention_name>
    <description>Liquid in vial (Concentrate for solution for infusion) for intravenous use</description>
    <arm_group_label>Dabrafenib + LTT462 + spartalizumab triplet arm 4</arm_group_label>
    <other_name>PDR001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a site of disease amenable to biopsy, and be a candidate for tumor&#xD;
             biopsy according to the treating institution's guidelines. Patients must be willing to&#xD;
             undergo a new tumor biopsy at baseline and during on study therapy. Exceptions may be&#xD;
             considered after documented discussion with Novartis.&#xD;
&#xD;
          -  All patients must have a BRAF V600 mutation confirmed by local assessment.&#xD;
&#xD;
          -  Patients with unresectable advanced/metastatic BRAF V600 cancer of the colon or rectum&#xD;
             with measurable disease as determined by RECIST v1.1&#xD;
&#xD;
          -  Patients must have documented disease progression following, or are intolerant to, 1&#xD;
             or 2 lines of chemotherapy for advanced/metastatic disease&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy, or in-situ cervical cancer, or&#xD;
             other tumors that will not affect life expectancy&#xD;
&#xD;
          -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             signficantly alter the absorption of study drugs&#xD;
&#xD;
          -  History of or current evidence/risk of retinal verin occlusion or serous retinopathy&#xD;
&#xD;
          -  History of or current interstitial lung disease or non-infectious pneumonitis&#xD;
&#xD;
          -  Patients with a known history of testing positive for HIV&#xD;
&#xD;
          -  Clinically significant cardiac disease at screening&#xD;
&#xD;
          -  Any medical condition that would, in the investigator's judgment, prevent the&#xD;
             patient's participation in the clinical study due to safety concerns or compliance&#xD;
             with clinical study procedures.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at Los Angeles Santa Monica Location</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Hernandez</last_name>
      <phone>310-582-4069</phone>
      <email>SCHernandez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Zev A. Wainberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Barnett</last_name>
      <email>kpbarnett@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Corcoran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Saunders</last_name>
      <email>Haley.Saunders@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Meredith Ann McKean</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari Gray</last_name>
      <phone>713-792-2921</phone>
      <email>migray@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Scott Kopetz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase Ib, BRAF-mutated, BRAF V600E, BRAF V600D, BRAF V600K, colorectal cancer, colon cancer, rectal cancer, metastatic, BLRM with EWOC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

